Table 1.
Cell cycle distribution (%)
| HT-29 | G0/G1 | S | G2/M |
| NT | 59,24 | 27,52 | 13,24 |
| E | 53,82 | 36,92 | 9,26 |
| Cx5 | 56,97 | 28,55 | 14,48 |
| Cx10 | 65,01 | 27,06 | 7,93 |
| Gb | 55,08 | 32,88 | 12,04 |
| Cx5+E | 53,24* | 30,08 | 16,68 |
| Cx10+E | 48,41 | 36,03 | 15,56 |
| Gb+E | 54,41 | 37,89 | 7,7 |
| Caco-2 | G0/G1 | S | G2/M |
| NT | 66,25 | 20 | 13,75 |
| E | 55,1* | 26,69 | 18,21 |
| Cx5 | 73,73 | 15,36 | 10,91 |
| Cx10 | 72,50 | 15,38 | 12,12 |
| Gb | 70,04 | 18,5 | 11,46 |
| Cx5+E | 57,20 | 21,13 | 21,67 |
| Cx10+E | 56,01* | 24,02 | 19,97 |
| Gb+E | 66,35 | 26,52 | 7,13 |
NT = untreated; E = Epidermal growth factor 10 nmol/L; Cx5 = cetuximab 5 nmol/L; Cx10 = cetuximab 10 nmol/L; Gb = gefitinib 1 μmol/L; Cx5 + E = cetuximab 5 nmol/L + Epidermal growth factor 10 nmol/L; Cx10 + E = cetuximab 10 nmol/L + Epidermal growth factor 10 nmol/L; Gb + E = gefitinib 1 μmol/L + Epidermal growth factor 10 nmol/L. ANOVA One-way analysis of variance Tukey's Multiple Comparison Test. Each point represents a mean of quadruplicate values.
*Statistically Significant